Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
Masakazu ToiFrances BoyleYoung-Hyuck ImMattea ReinischDavid MolthropZefei JiangRan WeiFrancisco SapunarBrenda R GrimesSarah Cassidy NabingerStephen R D JohnstonPublished in: The oncologist (2022)
The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2- early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).